Tags

Type your tag names separated by a space and hit enter

[Cost effectiveness of ACE inhibition in therapy of chronic heart failure in Switzerland: evaluation based on the SOLVD study].
Schweiz Med Wochenschr. 1997 Jul 22; 127(29-30):1234-41.SM

Abstract

BACKGROUND AND OBJECTIVES

Morbidity and mortality data in Switzerland underline the socioeconomic importance of heart failure. In the SOLVD study (Study on Left Ventricular Dysfunction), cardiovascular morbidity and mortality were reduced with the ACE inhibitor enalapril in patients with heart failure. The economic implications of this treatment were analyzed in a retrospective economic analysis from the perspective of Swiss third party payers.

PATIENTS AND METHODS

Source of the economic analysis was the SOLVD study data. This prospective study was placebo-controlled, double-blind and had a mean follow-up of 3.45 years (41.4 months), involving 2569 patients with heart failure, mainly in NYHA classes II and III. Costing data for treatment with enalapril, the per diem charges for hospitalization and the average length of hospital stay were retrieved from published national sources. The costs of in- and output were calculated and compared for the two treatment groups in a cost-efficacy analysis.

RESULTS

Additional treatment with enalapril resulted in an additional cost of 2.5 million Swiss francs. These incremental costs were, however, offset by reduced hospital costs (CHF 6.45 million savings) in the enalapril group. For the complete treatment cohort of the SOLVD study, the net savings were approximately 4.26 million Swiss francs.

CONCLUSIONS

From the clinical point of view, treatment with ACE inhibitors leads to a reduction in the progression of heart failure and reduced cardiovascular morbidity and mortality. With respect to health economics, it can be demonstrated that treatment with enalapril does not only offer clinical benefits, but that these also translate into impressive economic savings of CHF 3315 per patient.

Authors+Show Affiliations

Forschungsgruppe Medizinische Okonomie, München.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
English Abstract
Journal Article
Randomized Controlled Trial

Language

ger

PubMed ID

9333933

Citation

Szucs, T D., et al. "[Cost Effectiveness of ACE Inhibition in Therapy of Chronic Heart Failure in Switzerland: Evaluation Based On the SOLVD Study]." Schweizerische Medizinische Wochenschrift, vol. 127, no. 29-30, 1997, pp. 1234-41.
Szucs TD, Goedde M, Berger K, et al. [Cost effectiveness of ACE inhibition in therapy of chronic heart failure in Switzerland: evaluation based on the SOLVD study]. Schweiz Med Wochenschr. 1997;127(29-30):1234-41.
Szucs, T. D., Goedde, M., Berger, K., & Kiowski, W. (1997). [Cost effectiveness of ACE inhibition in therapy of chronic heart failure in Switzerland: evaluation based on the SOLVD study]. Schweizerische Medizinische Wochenschrift, 127(29-30), 1234-41.
Szucs TD, et al. [Cost Effectiveness of ACE Inhibition in Therapy of Chronic Heart Failure in Switzerland: Evaluation Based On the SOLVD Study]. Schweiz Med Wochenschr. 1997 Jul 22;127(29-30):1234-41. PubMed PMID: 9333933.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Cost effectiveness of ACE inhibition in therapy of chronic heart failure in Switzerland: evaluation based on the SOLVD study]. AU - Szucs,T D, AU - Goedde,M, AU - Berger,K, AU - Kiowski,W, PY - 1997/7/22/pubmed PY - 1997/10/23/medline PY - 1997/7/22/entrez SP - 1234 EP - 41 JF - Schweizerische medizinische Wochenschrift JO - Schweiz Med Wochenschr VL - 127 IS - 29-30 N2 - BACKGROUND AND OBJECTIVES: Morbidity and mortality data in Switzerland underline the socioeconomic importance of heart failure. In the SOLVD study (Study on Left Ventricular Dysfunction), cardiovascular morbidity and mortality were reduced with the ACE inhibitor enalapril in patients with heart failure. The economic implications of this treatment were analyzed in a retrospective economic analysis from the perspective of Swiss third party payers. PATIENTS AND METHODS: Source of the economic analysis was the SOLVD study data. This prospective study was placebo-controlled, double-blind and had a mean follow-up of 3.45 years (41.4 months), involving 2569 patients with heart failure, mainly in NYHA classes II and III. Costing data for treatment with enalapril, the per diem charges for hospitalization and the average length of hospital stay were retrieved from published national sources. The costs of in- and output were calculated and compared for the two treatment groups in a cost-efficacy analysis. RESULTS: Additional treatment with enalapril resulted in an additional cost of 2.5 million Swiss francs. These incremental costs were, however, offset by reduced hospital costs (CHF 6.45 million savings) in the enalapril group. For the complete treatment cohort of the SOLVD study, the net savings were approximately 4.26 million Swiss francs. CONCLUSIONS: From the clinical point of view, treatment with ACE inhibitors leads to a reduction in the progression of heart failure and reduced cardiovascular morbidity and mortality. With respect to health economics, it can be demonstrated that treatment with enalapril does not only offer clinical benefits, but that these also translate into impressive economic savings of CHF 3315 per patient. SN - 0036-7672 UR - https://www.unboundmedicine.com/medline/citation/9333933/[Cost_effectiveness_of_ACE_inhibition_in_therapy_of_chronic_heart_failure_in_Switzerland:_evaluation_based_on_the_SOLVD_study]_ L2 - https://medlineplus.gov/heartfailure.html DB - PRIME DP - Unbound Medicine ER -